innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
Company profile
Ticker
INVA
Exchange
Website
CEO
Geoffrey Hulme
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED MEDICINE INC, THERAVANCE INC
SEC CIK
Corporate docs
Subsidiaries
Advanced Medicine East, Inc • Innoviva Strategic Partners LLC • Innoviva Royalty Sub LLC • Innoviva TRC Holdings LLC • Innoviva Strategic Opportunities LLC • Innoviva Specialty Therapeutics Holdings LLC • Innoviva Specialty Therapeutics Inc. • Entasis Therapeutics Holdings Inc. • Entasis Therapeutics Inc. • Entasis Therapeutics Limited ...
IRS number
943265960
INVA stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
29 Feb 24
S-8
Registration of securities for employees
13 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
1 Nov 23
8-K
Innoviva Appoints Stephen Basso as Chief Financial Officer
25 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Aug 23
Latest ownership filings
4
Stephen Basso
7 Mar 24
4
Matthew Ronsheim
7 Mar 24
4
Marianne Zhen
7 Mar 24
4
Pavel Raifeld
7 Mar 24
SC 13D/A
Armata Pharmaceuticals, Inc.
4 Mar 24
4
Matthew Ronsheim
22 Feb 24
4
Marianne Zhen
22 Feb 24
SC 13G/A
PUTNAM INVESTMENTS LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.00 mm | 180.00 mm | 180.00 mm | 180.00 mm | 180.00 mm | 180.00 mm |
Cash burn (monthly) | (no burn) | 10.07 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 60.19 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 119.81 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 11.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 188 |
Opened positions | 17 |
Closed positions | 24 |
Increased positions | 61 |
Reduced positions | 85 |
13F shares | Current |
---|---|
Total value | 871.62 bn |
Total shares | 67.79 mm |
Total puts | 16.10 k |
Total calls | 43.30 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 9.44 mm | $122.67 bn |
Sarissa Capital Management | 7.28 mm | $94.53 bn |
Vanguard | 6.72 mm | $87.26 bn |
Putnam Investments | 6.26 mm | $81.34 bn |
Dimensional Fund Advisors | 4.45 mm | $57.82 bn |
Renaissance Technologies | 4.00 mm | $52.00 bn |
STT State Street | 2.37 mm | $30.76 bn |
Systematic Financial Management | 2.20 mm | $28.61 bn |
Westfield Capital Management | 2.05 mm | $26.56 bn |
Russell Investments | 1.29 mm | $16.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Zhen Marianne | Common Stock | Grant | Acquire A | No | No | 14.88 | 10,752 | 159.99 k | 47,566 |
5 Mar 24 | Zhen Marianne | Non-statutory Stock Option Common Stock | Grant | Acquire A | No | No | 14.88 | 23,022 | 342.57 k | 63,022 |
5 Mar 24 | Stephen Basso | Common Stock | Grant | Acquire A | No | No | 14.88 | 12,096 | 179.99 k | 12,096 |
5 Mar 24 | Stephen Basso | Non-statutory Stock Option Common Stock | Grant | Acquire A | No | No | 14.88 | 25,899 | 385.38 k | 175,899 |
5 Mar 24 | Matthew Ronsheim | Common Stock | Grant | Acquire A | No | No | 14.88 | 12,768 | 189.99 k | 40,778 |
5 Mar 24 | Matthew Ronsheim | Non-statutory Stock Option Common Stock | Grant | Acquire A | No | No | 14.88 | 27,338 | 406.79 k | 120,438 |
20 Feb 24 | Matthew Ronsheim | Common Stock | Payment of exercise | Dispose F | No | No | 15.8 | 807 | 12.75 k | 28,010 |
20 Feb 24 | Zhen Marianne | Common Stock | Payment of exercise | Dispose F | No | No | 15.8 | 2,862 | 45.22 k | 36,814 |